Hayley J Paholak
Overview
Explore the profile of Hayley J Paholak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Luan X, Paholak H, Burnett J, Stevers N, Sansanaphongpricha K, et al.
Nanomedicine (Lond)
. 2019 Dec;
15(1):77-92.
PMID: 31868112
We aim to demonstrate that a local nanoparticle-mediated hyperthermia can effectively eliminate tumor-associated Tregs and thereby boost checkpoint blockade-based immunotherapy. Photothermal therapy (PTT), mediated with systemically administered stealthy iron-oxide nanoparticles,...
2.
Chen H, Hu H, Tao C, Clauson R, Moncion I, Luan X, et al.
ACS Appl Mater Interfaces
. 2019 Jun;
11(27):23858-23869.
PMID: 31245984
Although the functionalization of magnetic nanoparticles (MNPs) with biomolecules has been widely explored for various biological applications, achieving efficient bioconjugations with a wide range of biomolecules through a single, universal,...
3.
Burnett J, Lim G, Li Y, Shah R, Lim R, Paholak H, et al.
Cancer Lett
. 2017 Mar;
394:52-64.
PMID: 28254410
Triple negative breast cancer (TNBC) typically exhibits rapid progression, high mortality and faster relapse rates relative to other breast cancer subtypes. In this report we examine the combination of taxanes...
4.
Paholak H, Stevers N, Chen H, Burnett J, He M, Korkaya H, et al.
Biomaterials
. 2016 Jul;
104:145-57.
PMID: 27450902
Increasing evidence suggesting breast cancer stem cells (BCSCs) drive metastasis and evade traditional therapies underscores a critical need to exploit the untapped potential of nanotechnology to develop innovative therapies that...
5.
Chen H, Ren X, Paholak H, Burnett J, Ni F, Fang X, et al.
ACS Appl Mater Interfaces
. 2015 May;
7(23):12814-23.
PMID: 26010660
Although many techniques exist for fabricating near-infrared (NIR)-resonant and magnetic resonance imaging (MRI)-capable nanomediators for photothermal cancer therapy, preparing them in an efficient and scalable process remains a significant challenge....
6.
Chen H, Zou H, Paholak H, Ito M, Qian W, Che Y, et al.
Polym Chem
. 2014 Apr;
5(8):2768-2773.
PMID: 24729795
Nanoparticles designed for biomedical applications are often coated with polymers containing reactive functional groups, such as -COOH and -NH, to conjugate targeting ligands or drugs. However, introducing highly charged surfaces...
7.
Zou P, Chen H, Paholak H, Sun D
Mol Pharm
. 2013 Sep;
10(11):4185-94.
PMID: 24033270
Understanding in vivo drug release kinetics is critical for the development of nanoparticle-based delivery systems. In this study, we developed a fluorescence resonance energy transfer (FRET) imaging approach to noninvasively...
8.
Korkaya H, Kim G, Davis A, Malik F, Henry N, Ithimakin S, et al.
Mol Cell
. 2012 Jul;
47(4):570-84.
PMID: 22819326
Although inactivation of the PTEN gene has been implicated in the development of resistance to the HER2 targeting antibody trastuzumab, the mechanisms mediating this resistance remain elusive. We generated trastuzumab...
9.
Zou P, Yu Y, Zheng N, Yang Y, Paholak H, Yu L, et al.
AAPS J
. 2012 Mar;
14(2):262-81.
PMID: 22407287
Quantitative estimations of first-in-human (FIH) doses are critical for phase I clinical trials in drug development. Human pharmacokinetic (PK) prediction methods have been developed to project the human clearance (CL)...